CRIZOTINIB相关论文
Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung can
...
Objective ALK is a prognostic and predictive tumor marker in non-small cell lung carcinoma(NSCLC),and is more often foun......
Next-generation sequencing identified a novel WDPCP-ALK fusion sensitive to crizotinib in lung adeno
Objective Lung cancer is the leading cause of cancer-related deaths worldwide.Over 85%of lung cancers are classified as ......
IsThereaProgression-freeSurvivalBenefitofFirst-lineCrizotinibversusStandardChemotherapya
目的 Tocomparetheprogression-freesurvival(PFS)ofChinesepatientswithALK-positive,advancedlungadenocarcinomawhoreceivedfir......
EfficacyandTolerabilityofCrizotinibintheTreatmentofALKpositive,AdvancedNon-small-cellLun
目的 Crizotinibhasbeenreportedtobeparticularlyeffectiveandtohaveacceptabletoxicityinadvancedanaplasticlymphomakinase(ALK......
A Case report of response to crizotinib in a squamous cell lung carcinoma patient harbouring EML4-AL
目的： We present a case of ALK gene translocation-squamous cell lung cancer which experienced a remarkable tumor response......
目的： EML4-ALK fusion positive non-small cell lung cancer (NSCLC) patients benefit from crizotinib treatment.However, the......
背景与目的 伴有脑转移的肺癌预后差.Crizotinib可有效治疗ROS1(C-ros oncogene 1 receptor tyrosine kinase)融合基因阳性的肺癌，......
会议
c-MET is a receptor protein-tyrosine kinase whose activating ligand is hepatocyte growth factor/scatter factor (HGF/SF).......
Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sens
Objective: Amplifications and activating mutations in the c-MET proto-oncogene are known oncogenic drivers that have......
目的建立高效液相色谱-质谱联用法测定人血浆中克唑替尼的质量浓度。方法用蛋白沉淀法处理血浆,色谱柱:Aglient ZORBAX XDB-C8柱,......
目的比较克唑替尼与含铂两药方案治疗棘皮动物微管结合蛋白4(EML4)-间变性淋巴瘤激酶(ALK)融合基因阳性晚期非小细胞肺癌(NSCLC)患......
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Ch
Objective:Crizotinib has demonstrated promising efficacy in patients with anaplastic lymphoma kinase (ALK)-positive non-......
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-s
...
蛋白酪氨酸激酶在细胞的信号转导和功能中发挥重要作用。ROS1是最新发现的2个酪氨酸激酶孤儿受体之一,目前对ROS1的天然配体的研究......
Crizotinib(商品名XALKORI)是1种酪氨酸激酶受体抑制剂,于2011年8月由美国FDA批准用于治疗FDA批准的检测方法确认为间变性淋巴瘤酶......
间变性淋巴瘤激酶(ALK)最早在间变性大细胞淋巴瘤(ALCL)中被发现,是ALCL的重要分子标志,近年来研究人员亦发现ALK基因在肿瘤的发生......
分子靶向药物的出现使癌症的治疗步入了新的阶段,与传统的化疗药物相比,具有瞄准特定的分子靶点、不良反应小和特异性强等。继EGFR......
Crizotinib是一种口服多激酶抑制药,针对c-Met和EML4-A LK融合基因为靶点,抑制肿瘤细胞增殖.Ⅰ期临床试验的推荐剂量为250 mg,每日......
肺癌是一种发病率、死亡率极高的恶性肿瘤。基于2008年GLOBOCAN统计，在男性患者中，肺癌的发病率居首。肺癌新发病例占新发癌症总数的......
学位
...
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
间变性淋巴瘤激酶(ALK)最早在间变性大细胞淋巴瘤(ALCL)中被发现,是ALCL的重要分子标志,近年来研究人员亦发现ALK基因在肿瘤的发生......
目的:分析克唑替尼联合沙利度胺治疗老年晚期非小细胞肺癌的药学价值。方法:选择老年晚期非小细胞肺癌患者68例,按照随机数字表法......
目的探讨克唑替尼对间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌(NSCLC)患者中枢神经系统(CNS)的影响。方法回顾性分析在河北大学附属......
目的探讨克唑替尼治疗ALK基因突变阳性晚期非小细胞肺癌的有效性和安全性。方法回顾性分析2015年1月—2018年12月就诊于我院的ALK......
目的建立测定克唑替尼含量和有关物质的HPLC法.方法采用C18VP-ODS柱（4.6×150mm,5μm）;以甲醇：0.1M磷酸氢二铵（60∶40）为流动相;检......
目的:观察克唑替尼对晚期非小细胞肺癌患者外周血清MMP-9表达的影响。方法:回顾性分析我院2015年1月-2016年12月收治的晚期非小细......
肺癌中大多数为非小细胞肺癌（non - small cell lung cancer，NSCLC）。目前，分子靶向治疗是NSCLC 的治疗中最有发展前景的部分。近年来，N......
肺癌中大多数为非小细胞肺癌（non - small cell lung cancer，NSCLC）。目前，分子靶向治疗是NSCLC 的治疗中最有发展前景的部分。近年来，N......
目的：研究间质表皮转化生长因子受体（MET）的表达与胃癌患者的临床病理特征、生存期、靶向药物克唑替尼的敏感性的关系。方法：采用免疫......
目的探讨克唑替尼治疗NSCLC的疗效及对其融合基因、相关血清指标和预后的影响分析。方法回顾性分析我科收治的60例EML4-ALK阳性表......
目的：观察肺腺癌细胞H2228克唑替尼耐药前后对化疗药物紫杉醇和顺铂敏感性变化，并探讨其可能机制。方法采用克唑替尼体外低浓度梯度......
ROS1基因重排/融合在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的发生率约为1%~2%。ROS1基因融合靶向药物的问世,明显改......
目的探讨克唑替尼治疗棘皮动物微管相关蛋白-间变性淋巴瘤激酶(echinoderm microtubuleassociated protein-like 4 gene and the a......
背景与目的肺癌患者常伴远处转移，其中伴骨髓转移患者治疗手段有限，预后差。Crizotinib已被证实可用于治疗间变淋巴瘤激酶（anaplastic......
背景与目的肺癌患者常伴远处转移，其中伴骨髓转移患者治疗手段有限，预后差。Crizotinib已被证实可用于治疗间变淋巴瘤激酶（anaplastic......
背景与目的克唑替尼是针对间变淋巴瘤激酶（anaplastic lymphoma kinase,ALK）融合基因、ROS-1重排等靶点的药物。本文观察克唑替尼治......
目的探讨克唑替尼联合化疗治疗非小细胞肺癌(NSCLC)的临床疗效。方法将60例NSCLC患者随机分为实验组和常规组,每组30例,常规组给予......
目的:提高对晚期肺腺癌胰腺转移致胰腺炎临床特点的认识,重视该类病人的分子靶向治疗.方法:回顾性分析我院收治的1例ALK阳性晚期肺......
Crizotinib-induced acute fatal liver failure in an Asian ALK-positive lung adenocarcinoma patient wi
BACKGROUND Crizotinib-induce hepatotoxicity is rare and non-specific, and severe hepatotoxicity can develop into fatal l......
目的：探讨肝细胞生长因子受体（cellular-mesenchymal to epithelial transition factor,c-MET）阳性的非小细胞肺癌（non-small cell lun......
以4-氯吡啶盐酸盐为起始原料,与1H-吡唑发生芳香亲核取代得到4-(1H-吡唑-1-基)吡啶盐酸盐,在Rh/C-20A的催化下对4-(1H-吡唑-1-基)......
Chemotherapy and targeted therapy remain the cornerstone of treatment of locally advanced and metastatic non-small cells......
Chemotherapy and targeted therapy remain the cornerstone of treatment of locally advanced and metastatic non-small cells......
Background: Overall survival (OS) and quality of life in patients with advanced non small cell lung cancer (NSCLC) remai......
Discordant tumor response in the treatment of ALK-rearranged non-small cell lung cancer leads to the
The advent of targeted molecular therapy against the EML4-ALK fusion gene is the latest therapeutic intervention for a s......
Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Transloca
Background: Crizotinib is a tyrosine kinase inhibitor of ALK, MET and ROS1. In a safety database trial, it was suggested......
